Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Priority Technology Holdings reported Q3 2026 revenue of $268.6 million, an 11.3% increase year-over-year, though net income fell 55.7% to $12.2 million. The company noted its pending go-private merger with WD Capital Partners for $8.05 per share is expected to close in the first half of 2027. Due to the pending acquisition, the company has suspended providing forward-looking guidance and will no longer host earnings conference calls.
IMAX Corporation reported record-breaking third quarter 2026 financial results, achieving its best quarterly performance in company history driven by the success of Christopher Nolan’s 'The Odyssey'. The company saw revenue surge 64% to $175 million and global box office reach a record $712 million, while net income per diluted share rose 430% to $1.96.
Term
Q3 2026
“What IMAX achieved goes beyond simply a ‘great quarter’ and transcends the many records we shattered in the period. What we believe we are witnessing is an awakening to the power and potential of our platform to impact global culture, unlock new commercial opportunities, and inspire a new level of demand and awe in audiences around the world.”
Rich Gelfond, CEO of IMAX Corporation
“Christopher Nolan’s The Odyssey is a historic cinematic achievement crafted entirely with IMAX technology and its record-breaking success marks a new era of opportunity for our company. The record margins we generated in the quarter demonstrate the unique strength of our model, and the growing value of scarce events and experiences in an increasingly A.I.-driven world underscore a powerful opportunity for our business, as we look ahead to a remarkably strong slate over the next several years.”
Loar Holdings reported record Q3 2026 net sales of $176.2 million, a 39% increase year-over-year, driven by 15.8% organic growth and recent acquisitions. While Adjusted EBITDA rose 46.5% to $71.9 million, net income declined to $19.6 million due to higher interest and tax expenses. The company also raised its financial outlook for both full-year 2026 and 2027.
“Our record results in the third quarter of 2026 reflects our continued successful execution along all our value drivers. Most noteworthy our operating cash flow for the quarter after being reduced by our capital expenditures were a record for the quarter improving 46% over the comparative previous year period.”
Dirkson Charles, Loar Holdings Chief Executive Officer and Executive Co-Chairman of the Board of Directors
CRA International reported fiscal year-to-date 2026 revenues of $626.7 million, a 13% increase over the prior year, though net income decreased slightly to $38.5 million. The company significantly increased its debt position with a new $72.9 million term loan and higher revolving credit usage to fund operations and $49.3 million in share repurchases.
OFA Group is effecting a 10-for-1 reverse stock split (share consolidation) of its Class A ordinary shares, effective November 10, 2026. The action is intended to increase the per-share trading price to support the company's continued listing on the Nasdaq Capital Market. The split will reduce the number of outstanding Class A shares from approximately 9 million to approximately 0.9 million.
Intellia Therapeutics reported Q3 2026 financial results, highlighting the FDA's acceptance and Priority Review of the BLA for lonvo-z with a PDUFA date of March 10, 2027. The company completed enrollment in its MAGNITUDE-2 Phase 3 trial for ATTRv-PN and expects its current cash position to fund operations into 2028.
Counterparty
Regeneron Pharmaceuticals, Inc.
Term
Q3 2026
“This is a defining period for Intellia as we advance our late-stage pipeline and prepare for a transformative year ahead. We have assembled the teams and capabilities needed to support a successful launch in HAE while also continuing to advance nex-z’s Phase 3 clinical trials and our pipeline expansion efforts. Looking to 2027, we are working toward a historic milestone: the potential approval of lonvo-z as the world’s first in vivo CRISPR-based therapy.”
John Leonard, M.D., Intellia President and Chief Executive Officer
Centuri Holdings reported record third-quarter 2026 revenue of $1.2 billion, a 40% year-over-year increase, driven by workforce investments and improved operational efficiency. The company achieved net income of $26.9 million and expanded its opportunity pipeline to a record $19 billion. Management issued preliminary 2027 targets including mid-teens revenue growth and gross profit margins between 8.5% and 9.0%.
Term
Q3 2026
“I am very pleased with our third quarter results that clearly demonstrate that investments made to build greater scale and capacity during the first half of the year, including our workforce additions, delivered the benefits we expected as productivity and efficiency improved across our operations.”
Christian Brown, President & CEO
“Commercial momentum remains strong across our end markets, supported by robust customer demand and significant opportunities across our core and adjacent end markets. Through the first three quarters of the year, we have secured approximately $2.9 billion of bookings.”
White Mountains Insurance Group reported a 1% decrease in book value per share to $2,243 for Q3 2026, primarily driven by unrealized investment losses at MediaAlpha and the impact of higher interest rates on fixed income. Despite the investment headwinds, operating results were solid with Ark producing a 75% combined ratio and HG Global generating record gross written premiums of $19 million.
Term
Q3 2026
“Book value per share was down 1% in the quarter. Higher interest rates and a lower share price at MediaAlpha drove unrealized investment losses, which offset an otherwise solid quarter for operating results. Ark produced a 75% combined ratio and $386 million of gross written premiums, leading to strong growth in tangible book value.”
Acorn Energy reported net income of $1.17 million for the nine months ended September 30, 2026, compared to $1.46 million in the prior year period. The company completed the acquisition of the Gen-Tracker business during the period, resulting in the recognition of $1.44 million in goodwill and $2.08 million in intangible assets.
Hertz reported its strongest quarterly revenue and Adjusted Corporate EBITDA in three years for Q3 2026, driven by strong pricing in its core U.S. rental business. Revenue rose 6% year-over-year to $2.6 billion, while Adjusted Corporate EBITDA reached $233 million, reflecting continued progress in the company's operational transformation.
Term
Q3 2026
“We delivered our strongest quarterly revenue and Adjusted Corporate EBITDA performance in three years, driven by continued revenue growth and margin expansion on flat capacity. The underlying progress in our core U.S. rental business is meaningful, and we see significant opportunity ahead as we continue to improve execution, expand our franchise model and build new sources of earnings and value across the Hertz platform.”
CRA International reported record third-quarter 2026 revenue of $214.9 million, a 15.6% increase year-over-year, driven by broad-based growth across its Legal & Regulatory and Management Consulting practices. The company increased its full-year 2026 revenue guidance and raised its quarterly dividend by 17.5% to $0.67 per share.
Term
Q3 2026
“CRA continues to build on its strong start to fiscal 2026 as third-quarter revenue increased 15.6% year over year to $214.9 million. This record top-line performance translated into the highest third-quarter profits in the company’s history as measured by net income, earnings per diluted share and EBITDA.”
Paul Maleh, CRA’s President and Chief Executive Officer
“Broad-based contributions once again characterized CRA’s financial performance, reflecting both the quality and the depth of our portfolio. Seven practices grew year over year, representing approximately 95% of the company’s total revenue for the third quarter.”
Paul Maleh, CRA’s President and Chief Executive Officer
Filana Therapeutics reported Q3 2026 financial results, including a net loss of $10.7 million and a cash balance of $47.0 million. The company announced that patient screening for its Phase 2a study of simufilam in TSC-related epilepsy is expected to begin by Q1 2027 following the recent lifting of an FDA clinical hold.
“Simufilam has the potential to make a meaningful difference for patients with TSC-related epilepsy. We began working toward activating clinical study sites as soon as FDA lifted the clinical hold in September. Patient screening is expected to begin by the first quarter of 2027.”
Processa Pharmaceuticals issued a stockholder letter outlining its strategic shift toward immunological and inflammatory (I&I) diseases following its July acquisition of Vidya Therapeutics. The company highlighted the advancement of its lead BTK inhibitor candidate, VT-7208, into Phase 2 development for food allergy, chronic spontaneous urticaria, and relapsing multiple sclerosis, supported by approximately $183.3 million in net cash proceeds.
Axcelis Technologies reported Q3 2026 revenue of $237.8 million and GAAP diluted EPS of $1.21, exceeding internal expectations. The company noted a strong increase in bookings and record revenue in its CS&I business, signaling a broadening recovery across Memory, Power, and General Mature end markets.
Term
Q3 2026
“We are pleased with our third quarter performance, as improving demand drove sequential growth in systems revenue, complemented by another quarterly record in CS&I. We are particularly encouraged by the strong increase in bookings, reflecting a broadening recovery across our end markets, with continued momentum in Memory and increasing activity in Power and General Mature.”
Russell Low, President and CEO
“Our third quarter results exceeded our expectations, supported by stronger shipments and record CS&I revenue, despite the impact from foreign exchange headwinds on our gross margin. We continue to generate healthy cash flow and maintain a strong balance sheet, providing us with ample financial flexibility.”
David Ryzhik, Senior Vice President and Interim CFO
Southern Company reported third-quarter 2026 earnings of $2.0 billion, or $1.77 per share, compared to $1.7 billion in the prior year period. Operating revenues increased 13% to $8.8 billion, driven by warmer weather, customer growth, and increased usage from large commercial and industrial customers.
Term
Q3 2026
“The Southeast is growing at a pace that is both unprecedented and transformational, and we believe Southern Company is well positioned for today and in the future. Our scale, our experience and our customer-focused strategy allow us to serve this growing demand in a responsible and sustainable manner, with the same discipline, credibility and customer focus that have long defined our company.”
Chris Womack, chairman, president and CEO of Southern Company
Core Scientific reported a significant shift in its business model, with colocation revenue growing to $215.4 million for the quarter ended September 30, 2026, compared to $15.0 million in the prior year, driven by high-performance computing (HPC) initiatives. Despite a net loss of $324.4 million for the nine-month period, the company achieved a net income of $1.18 billion in the third quarter, primarily due to a $1.03 billion favorable change in the fair value of warrant liabilities.
USA TODAY Co. reported third quarter 2026 total revenues of $519.2 million, a 7.4% year-over-year decrease, and a net loss of $4.6 million. The company announced a new $100 million annualized cost reduction program and plans to opportunistically repurchase shares using $96.9 million remaining in its authorized buyback program. Management also highlighted a $901 million damages calculation in its ongoing Ad Tech litigation against Google, with a trial date set for April 2027.
Term
Q3 2026
“In the third quarter, we felt the impacts of the changes in consumer search along with some inflationary pressures. At the same time, we saw encouraging underlying signals in the categories that we believe are most important to our future. Audience trends showed signs of stabilization, engagement strengthened across our platforms, and we continued to grow the digital revenue categories that are central to our strategy, including direct-sold digital advertising, digital-only subscriptions, and digital other.”
Michael Reed, Chairman and Chief Executive Officer
“At the end of the third quarter, we implemented our new $100 million annualized cost reduction program, establishing a lower cost structure that is already benefiting our fourth-quarter run rate. Together with the positive momentum across our digital portfolio, we expect these improvements to drive significant sequential growth in Adjusted EBITDA and free cash flow, as well as substantial margin expansion in the fourth quarter.”
Michael Reed, Chairman and Chief Executive Officer
Novavax reported Q3 2026 total revenue of $68 million and raised its full-year 2026 revenue guidance to $400 million at the mid-point. The company also earned a $125 million milestone payment from partner Sanofi following the initiation of a Phase 3 combination vaccine trial in Europe.
“This quarter, we continued to execute across all three pillars of our strategy. Our partner Sanofi initiated their Phase 3 influenza-COVID-19 combination vaccine trial vaccine trial in Europe, triggering a $125 million milestone payment. Our focused R&D efforts are building a growing body of data on what our technology can do in infectious disease, advancing our C. difficile candidate towards the clinic and exploring oncology as a potential new area of application. And we have been doing this while continuing to reduce expenses and operate with financial discipline. Over time, we believe this strategy can build a robust and profitable Novavax, with multiple partners and products, diversified revenue streams and a meaningful impact on global health.”
John C. Jacobs, President and Chief Executive Officer, Novavax
Camden National Corporation has prepared a formal investor presentation for use in upcoming meetings with investors and analysts. The presentation, filed as Exhibit 99.1, provides a strategic and operational overview of the company's performance and market position in the Northern New England region.
Insight Enterprises reported Q3 2026 financial results with consolidated net sales increasing 22% year-over-year to $2.4 billion. While GAAP net earnings fell 57% due to earnout valuation adjustments and restructuring costs, adjusted diluted EPS grew 34% to $3.59, driven by strong performance in infrastructure hardware and cloud services.
Term
Q3 2026
“We delivered another strong quarter, with broad-based momentum across our business. Gross profit increased 20%, adjusted earnings from operations grew 23%, and adjusted diluted earnings per share increased 34%.”
Jack Azagury, President and Chief Executive Officer
“We continue to see strong performance in our strategic growth priorities, with infrastructure hardware gross profit increasing more than 50% and more than 20% gross profit growth across Cloud and Insight Core Services.”
Jack Azagury, President and Chief Executive Officer
InMed Pharmaceuticals completed a 1-for-10 reverse stock split (consolidation), reducing its outstanding shares from approximately 5.49 million to 549,374. The company also legally changed its name to Mentari Therapeutics, Inc. and confirmed shareholder approval of all matters at its 2026 Annual General and Special Meeting.
Acorn Energy reported Q3 2026 revenue growth of 4.6% to $2.59 million and net income of $0.94 million, which included a $780,000 deferred income tax benefit. During the quarter, the company completed the acquisition of Gen-Tracker to expand its commercial generator monitoring portfolio and annual recurring revenue.
Term
Q3 2026
“Our third quarter was a solid, cash-generative quarter driven by a 4.6% revenue increase compared to Q3’25, with approximately $1M of cash generated from operations. Our Q3’26 EPS included a $730,000 income tax benefit related to a further reduction in the valuation allowance on our deferred tax assets, reflecting increased confidence in our ability to utilize our net operating loss (NOL) carryforwards in the future.”
Vericel reported third quarter 2026 total revenue growth of 26% to $85.4 million and a 179% increase in net income to $14.2 million. Driven by strong performance in its MACI and Burn Care segments, the company raised its full-year 2026 revenue guidance to a range of $344 million to $346 million.
Term
Q3 2026
“The Company delivered outstanding financial and business results in the third quarter as we continue to generate top-tier revenue and profit growth as well as significant free cash flow, while also returning capital to shareholders.”
Nick Colangelo, President and CEO of Vericel
“Given our third quarter outperformance and the strong start to the fourth quarter for both commercial businesses, and particularly for MACI, we believe that the Company is very well-positioned for a strong close to 2026 and to sustain this momentum in 2027 and beyond.”
International Seaways, Inc. reported a significant increase in net income for the nine months ended September 30, 2026, reaching $925.3 million compared to $181.8 million in the prior year. This growth was driven by a substantial rise in shipping revenues across pool, time charter, and voyage charter segments, alongside a $140.9 million gain on the disposal of vessels.
Avalo Therapeutics entered into an at-the-market (ATM) sales agreement with Jefferies LLC to establish a program for the potential issuance and sale of up to $200 million of common stock. Simultaneously, the company terminated its existing sales agreement with TD Securities (USA) LLC (formerly TD Cowen) that had been in place since June 2025.
BlackRock TCP Capital Corp. reported third quarter 2026 financial results, including net investment income of $13.4 million ($0.16 per share) and a net decrease in net assets from operations of $66.8 million. The company also declared a fourth quarter dividend of $0.17 per share and highlighted the completion of a major portfolio sale to Pantheon which significantly reduced leverage.
“Strong repayment and realization activity this quarter, together with proceeds from the portfolio sale, significantly reduced leverage and meaningfully enhanced liquidity in the portfolio. Together, these steps place TCPC on a strong foundation as the Board conducts its ongoing strategic review, which is focused on achieving the best possible outcome for shareholders.”
Jason Mehring, Chairman and Chief Executive Officer
Lifetime Brands reported Q3 2026 net sales of $177.7 million, a 3.4% increase year-over-year, driven by strong international growth and home décor performance. The company also announced that its Board of Directors authorized an increase to its share repurchase program, bringing the total available for buybacks to $20 million.
“We delivered net sales growth of 3.4% and expanded gross margin by 140 basis points in the third quarter as momentum continues across key parts of the business. International sales grew 18.8% and the segment approached breakeven as Project Concord takes hold. Home décor continues to grow, our Farberware relaunch is performing well, and our Dollar General partnership, launched in 2024, is on track to approach $20 million in sales this year. This year’s refinancing lowered our borrowing costs and strengthened our financial flexibility, and our new $20 million share repurchase authorization provides additional flexibility to return capital to shareholders. We look forward to sharing our capital allocation strategy and the tailwinds we see for 2027 at our Investor Day on December 1st.”
Ralph Lauren Corporation reported second quarter fiscal 2027 results that exceeded expectations, with revenue increasing 9% to $1.8 billion. The company raised its full-year fiscal 2027 outlook for revenue and operating margin based on strong first-half performance and brand momentum across all regions.
Term
Q2 2027
“As we enter the Holiday season, I'm reminded of what has always inspired me — the beauty of the world around us, the warmth of family and the optimism and sense of possibility that have guided us for nearly 60 years. These values are deeply personal to me and remain at the heart of our Company and everything we create.”
Ralph Lauren, Executive Chairman and Chief Creative Officer
“We delivered strong second quarter performance, enabling us to raise our Fiscal 2027 outlook once again. Through a dynamic global operating environment, we continue to invest in the strategic priorities that are bringing our Next Great Chapter: Drive plan to life — strengthening our brand desirability and delighting multi-generational customers in every geography around the world to drive sustainable long-term growth and value creation.”
Patrice Louvet, President and Chief Executive Officer
Jerash Holdings (US), Inc. announced that its board of directors has declared a regular quarterly cash dividend of $0.05 per share of common stock. The dividend is scheduled to be paid on or about November 23, 2026, to stockholders of record as of November 16, 2026.
Shattuck Labs reported a net loss of $55.1 million for the nine months ended September 30, 2026, compared to $36.2 million in the prior year period, driven primarily by a significant increase in research and development expenses. The company strengthened its balance sheet during the period, ending with $201.6 million in total current assets following common stock offerings and warrant exercises.